A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects

NCT02688387 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension, Pulmonary

Interventions

DRUG: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose
DRUG: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)

Sponsor

GlaxoSmithKline

Collaborators

[object Object]
[object Object]